Skip to main navigation Skip to search Skip to main content

Transforming ovarian cancer care by targeting minimal residual disease

  • Amir A. Jazaeri*
  • , Rachel Grisham
  • , Anne Knisely
  • , Stefani Spranger
  • , Dmitriy Zamarin
  • , R. Tyler Hillman
  • , Barrett C. Lawson
  • , Kathleen H. Burns
  • , Sanghoon Lee
  • , Shannon N. Westin
  • , Enrico Moiso
  • , Marc J. Williams
  • , Neelkanth M. Bardhan
  • , Thomas Pisanic
  • , Ursula Matulonis
  • , Britta Weigelt
  • , Ie Ming Shih
  • , Panagiotis A. Konstantinopoulos
  • , Stephanie Gaillard
  • , Linghua Wang
  • Carol Aghajanian, Alan D. D'Andrea, Paula Hammond, Sohrab Shah, Kai W. Wucherpfennig, Karen H. Lu
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • Massachusetts Institute of Technology
  • Dana-Farber Cancer Institute
  • Break Through Cancer
  • Johns Hopkins University

Research output: Contribution to journalComment/debate

6 Scopus citations

Abstract

Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.

Original languageEnglish
Pages (from-to)755-760
Number of pages6
JournalMed
Volume4
Issue number11
DOIs
StatePublished - 10 11 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Transforming ovarian cancer care by targeting minimal residual disease'. Together they form a unique fingerprint.

Cite this